Furthermore, the second-generation BTK inhibitor acalabrutinib has also been approved by the FDA for treatment of mantle cell lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma. This evidence concerns the gene BTK and mantle cell lymphoma.